In rodent stroke models, pharmacologic or genetic reduction in PCSK9 lowers cytokine release, reduces microglial activation, and improves tissue outcomes, with signaling changes that map to Toll-like receptor and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) pathways in microglia and endothelium [15,129,130]. This evidence concerns the gene PCSK9 and Stroke.